Last update April 1, 2019
Very Low Risk
An association of a polysaccharide (glucomannan) obtained from Candida utilis and a protein rich in glutamine obtained from ungerminated seeds of Ricinus communis on an inorganic matrix of calcium sulphate and phosphate.
Oral administration 3 times a day.
Since the last update we have not found any published data on its excretion in breast milk.
Its high molecular weight makes transfer into breastmilk in significant quantities unlikely.
Due to its protein and glucidic nature it is digested in the intestine, so it has a low oral bioavailability (CECMED 2015), which hinders passage to infant plasma from breastmilk.
It has no side effects.
Its efficacy as an immunomodulator is not proven (Murciasalud 2006).
The literature on this drug is scarce and/or out-of-date, and it is sold in few countries.
It has zero or low therapeutic utility, and is totally non-essential.
We do not have alternatives for Phosphoglycopeptical since it is relatively safe.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2006 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM